论文部分内容阅读
目的 :探讨益气化痰散结方联合XELOX化疗方案治疗晚期复发性结肠癌的临床疗效。方法:将60例晚期复发性结肠癌患者随机分成对照组和治疗组各30例,对照组予XELOX方案化疗:奥沙利铂130 mg/m2,静滴,第1 d;希罗达1000 mg/m2,口服,每日2次,第1~14 d;治疗组在化疗的同时内服益气化痰散结方,均21 d为1个周期。3周期后对临床近期疗效、疾病无进展生存期(PFS)、不良反应及生活质量进行评估。结果:两组治疗后,治疗组和对照组的有效率分别为56.7%,50.0%,两组比较差异无统计学意义(P>0.05);治疗组的中位PFS为(254.00±6.25)d,对照组的中位PFS为(217.00±7.38)d,治疗组优于对照组(P<0.05);治疗组与对照组血液学毒性主要表现为白细胞减少,发生率分别为53.3%和70.0%;恶心呕吐的发生率分别为40.0%,56.7%,治疗组明显低于对照组,两组比较有显著差异(P<0.05)。两组患者在治疗后生活质量评分均有明显升高,与治疗前比较差异有统计学意义(P<0.05),两组治疗后比较差异亦有统计学意义(P<0.05)。结论:与单纯化疗相比较,益气化痰散结方与化疗联合能进一步延长晚期结肠癌患者疾病无进展生存期,改善生活质量,并降低化疗毒副反应。
Objective: To investigate the clinical efficacy of Yiqi Huatan Sanjie Decoction combined with XELOX chemotherapy in the treatment of advanced recurrent colon cancer. Methods: Sixty patients with advanced recurrent colon cancer were randomly divided into control group and treatment group, 30 cases in each group. The control group received XELOX chemotherapy: oxaliplatin 130 mg / m2, intravenous drip, first day, Xeloda 1000 mg / m2, orally, 2 times a day, 1 ~ 14 d; the treatment group in the chemotherapy while taking Yiqi Huatan Sanjie side, 21 d for a cycle. Three cycles after the clinical efficacy, progression-free survival (PFS), adverse reactions and quality of life were assessed. Results: After treatment, the effective rates of the treatment group and the control group were 56.7% and 50.0% respectively, with no significant difference between the two groups (P> 0.05). The median PFS in the treatment group was (254.00 ± 6.25) d , And the median PFS in the control group was (217.00 ± 7.38) d, which was higher in the treatment group than in the control group (P <0.05). The hematologic toxicity of the treatment group and the control group was mainly leukopenia, the incidence rates were 53.3% and 70.0% The incidences of nausea and vomiting were 40.0% and 56.7% respectively, which were significantly lower in the treatment group than those in the control group (P <0.05). The quality of life scores of both groups were significantly increased after treatment, with statistical significance (P <0.05), and there was significant difference between the two groups after treatment (P <0.05). Conclusion: Compared with chemotherapy alone, Yiqi Huatan Sanjie combined with chemotherapy can further prolong the progression-free survival of patients with advanced colon cancer, improve the quality of life, and reduce the side effects of chemotherapy.